




## Local Perspectives and Consideration on RWD/RWE

Wednesday, 24<sup>th</sup> April 2024

Dr. Panu Looareesuwan, Ph.D.

Prof. Dr. Ammarin Thakkinstian, Ph.D.





### Outline

- Department of Clinical Epidemiology and Biostatistics (CEB).
- Real-world data (RWD).
  - CEB data warehouse
  - How it was created
- · Our projects.






### About me

- Graduate with Ph.D. in Data Science for Healthcare from Mahidol university in 2022.
- Work as Data Analyst / Informatician for 4 years at Thai Health Information Standards
  Development Center (THIS) and now CEB as lecturer / Data scientist.
- Focus on Applied Research, Machine Learning, Tabular data, Computer Vision, Natural Language Processing.

Data Warehouse




## Who are we?






Our roles








Our research















# Importance of RWD

- · Cost efficiency.
- · Rich datasets, rich set of features and datapoint.
- · Generate RWE.
- Enhanced external validation and increase reliability.
- Improve patient outcome.













Applying EC

Data retrieval

Patient identification

Cohort creation


Updating

#### To form cohort data requires

- Principal investigator
  - Coordinating all participants.
- Physicians/Specialists
  - Providing content expertise.
- Epidemiologists/Biostatisticians
  - Developing research framework and statistical analysis.
- Data scientists
  - Handling big data and provide machine learning analysis.
- Data engineers
  - Designing database architecture and managing/maintaining data warehouse server for cohort data.


Data Warehouse

Form team Applying EC Data retrieval Patient identification Cohort creation Updating






Updating









Form team

Applying EC

Data retrieval

Patient identification

Cohort creation

Updating

Exact criteria for T2D patient identification

Inclusion:

Patients identified with ICD-10 of E11\*.

Patients who was prescribed with anti-diabetic medications.

Patients who have high glycemic level.

**Exclusion** 


Patients age less than 18 years.

Patients identified with ICD-10 of E10\*.

Patients with GDM.








Cohort creation				
Updating				

ID	Date	ICD10	Gender	
001	01-01-2011			
001	26-10-2012			
001	12-12-2012			
002	03-01-2011			
002	15-06-2011			








## T2D cohort










# Variables (Features)

- ~300 variables from various data domains (e.g., patients' demographics, physical examinations, medications, diagnosis, laboratory tests, and etc.)
- Longitudinal data

Laboratory tests	Demographic Medications		Comorbidities / Complications	
Albumin Urine, mg/dL	BMI, kg/m2	Alpha glucosidase inhibitors	Hypertension	
Blood urea nitrogen, mg/dL	Height, cm	Beta blockers	Dyslipidemia	
eGFR (CKD-EPI), ml/min/1.73 m\S\2	Weight, kg	Biguanides	Diabetic Retinopathy (DR)	
Creatinine, mg/dL	Insurance Scheme	Sulfonylureas	Chronic Kidney Disease (CKD)	
FPG, mg/dL	SBP, mmHg	Insulin	Peripheral Vascular Diseases (PVD)	
HbA1C (EDTA-blood), %	DBP, mmHg	SGLT-2i	Cardiovascular Disease (CVD)	
Cholesterol, mg/dL	,	DPP-4i	Heart Failure (HF)	
HDL Cholesterol, mg/dL		GLP1-RA	Fracture	. (
LDL Cholesterol, mg/dL		Meglitinides	Death	14/-
Triglyceride, mg/dL		Thiazolidinediones	Data	. vva
Troponin T, ng/L		Calcium channel blocker		
Uric acid, mg/dL		Calcium phosphate binders		
AST, U/L		Diuretics		
ALT, U/L		Statins		
GGT, U/L		ACE inhibitor		





# Our productivity

Clinical effectiveness of second-line antihyperglycemic drugs on major adverse cardiovascular events: An emulation of a target trial

Sukanya Siriyotha <sup>1</sup>, Thitiya Lukkunaprasit <sup>2</sup>, Teeranan Angkananard <sup>3</sup>, Panu Looareesuwan <sup>1</sup>, Gareth J McKay <sup>4</sup>, John Attia <sup>5</sup>, Ammarin Thakkinstian <sup>1</sup>

Effects of second-line antihyperglycemic drugs on the risk of chronic kidney disease: applying a target trial approach to a hospital-based cohort of Thai patients with type 2 diabetes

Sukanya Siriyotha, Thitiya Lukkunaprasit <sup>™</sup>, Panu Looareesuwan, Hataikarn Nimitphong, Gareth J. McKay, John Attia & Ammarin Thakkinstian

■IQVIA

A multicentre retrospective study of characterization of treatment intensified (add on to metformin) real world adult population with type 2 diabetes mellitus in India, Pakistan, and Thailand

Retinopathy prediction in type 2 diabetes: Time-varying Cox proportional hazards and machine learning models

Panu Looareesuwan <sup>a</sup>, Suparee Boonmanunt <sup>a</sup>, Sukanya Siriyotha <sup>a</sup>, Thitiya Lukkunaprasit <sup>b</sup>,





# Our productivity

 Collaboration between Siriraj, Khon Kaen University and Ramathibodi hospital, multicenter study.









## Our team





































## Additional information

https://www.rama.mahidol.ac.th/ceb/





# Thank you

